Prevention of allergy by virus‐like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model

In high‐risk populations, allergen‐specific prophylaxis could protect from sensitization and subsequent development of allergic disease. However, such treatment might itself induce sensitization and allergies, thus requiring hypoallergenic vaccine formulations. We here characterized the preventive potential of virus‐like nanoparticles (VNP) expressing surface‐exposed or shielded allergens.

[1]  W. Pickl,et al.  All the small things: How virus‐like particles and liposomes modulate allergic immune responses , 2019, European journal of immunology.

[2]  P. Briza,et al.  Similar Allergenicity to Different Artemisia Species Is a Consequence of Highly Cross-Reactive Art v 1-Like Molecules , 2019, Medicina.

[3]  R. Valenta,et al.  Recombinant allergens for immunotherapy: state of the art , 2019, Current opinion in allergy and clinical immunology.

[4]  R. Valenta,et al.  Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice , 2018, EBioMedicine.

[5]  W. Fokkens,et al.  Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications , 2018, Allergy.

[6]  E. Burchard,et al.  Dysregulated invertebrate tropomyosin–dectin-1 interaction confers susceptibility to allergic diseases , 2018, Science Immunology.

[7]  M. Vogel,et al.  Allergens displayed on virus‐like particles are highly immunogenic but fail to activate human mast cells , 2018, Allergy.

[8]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[9]  C. Bain,et al.  Barrier-tissue macrophages: functional adaptation to environmental challenges , 2017, Nature Medicine.

[10]  J. Paul Robinson,et al.  Guidelines for the use of flow cytometry and cell sorting in immunological studies. , 2017, European journal of immunology.

[11]  I. Bellinghausen,et al.  Recent advances in the use of nanoparticles for allergen‐specific immunotherapy , 2017, Allergy.

[12]  W. Pickl,et al.  Pharmacological targeting of allergen-specific T lymphocytes. , 2017, Immunology letters.

[13]  F. Levi-Schaffer,et al.  MicroRNA‐4443 regulates mast cell activation by T cell–derived microvesicles , 2017, The Journal of allergy and clinical immunology.

[14]  S. Durham,et al.  Novel approaches and perspectives in allergen immunotherapy , 2017, Allergy.

[15]  B. Lipworth,et al.  Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction. , 2017, The Journal of allergy and clinical immunology.

[16]  R. Valenta,et al.  Recombinant allergy vaccines based on allergen-derived B cell epitopes , 2017, Immunology letters.

[17]  R. Valenta,et al.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy , 2016, EBioMedicine.

[18]  Carsten Flohr,et al.  Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. , 2016, The New England journal of medicine.

[19]  J. Bousquet,et al.  Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study. , 2016, The Journal of allergy and clinical immunology.

[20]  R. Valenta,et al.  Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future , 2016, The Journal of allergy and clinical immunology.

[21]  W. Pickl,et al.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy) , 2016, International Archives of Allergy and Immunology.

[22]  B. Chipps,et al.  Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy , 2015, Pediatrics.

[23]  H. Stockinger,et al.  Rapid multiplex analysis of lipid raft components with single-cell resolution , 2015, Science Signaling.

[24]  A. Neunkirchner,et al.  CD8+ T Cell Fate and Function Influenced by Antigen-Specific Virus-Like Nanoparticles Co-Expressing Membrane Tethered IL-2 , 2015, PloS one.

[25]  J. Bousquet,et al.  Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. , 2015, The Journal of allergy and clinical immunology.

[26]  G. Roberts,et al.  Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy , 2015, Pediatrics.

[27]  L. Klimek,et al.  Is The Allergen Really Needed in Allergy Immunotherapy? , 2014, Current Treatment Options in Allergy.

[28]  C. Akdis,et al.  Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. , 2014, The Journal of clinical investigation.

[29]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.

[30]  H. Perlman,et al.  Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. , 2013, American journal of respiratory cell and molecular biology.

[31]  N. Bjarnason.  Dupilumab in persistent asthma. , 2013, The New England journal of medicine.

[32]  Daniela Wojta-Stremayr,et al.  Fluorosomes: Fluorescent Virus-Like Nanoparticles that Represent a Convenient Tool to Visualize Receptor-Ligand Interactions , 2013, Sensors.

[33]  M. Fei,et al.  Cutting Edge: Inhaled Antigen Upregulates Retinaldehyde Dehydrogenase in Lung CD103+ but Not Plasmacytoid Dendritic Cells To Induce Foxp3 De Novo in CD4+ T Cells and Promote Airway Tolerance , 2013, The Journal of Immunology.

[34]  L. Klimek,et al.  Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs , 2013, American journal of rhinology & allergy.

[35]  Zbigniew Mikulski,et al.  Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance , 2013, The Journal of experimental medicine.

[36]  L. Cox,et al.  New Directions in Immunotherapy , 2013, Current Allergy and Asthma Reports.

[37]  A. Casset,et al.  Varying Allergen Composition and Content Affects the in vivo Allergenic Activity of Commercial Dermatophagoides pteronyssinus Extracts , 2012, International Archives of Allergy and Immunology.

[38]  J. Guillen.  FELASA guidelines and recommendations. , 2012, Journal of the American Association for Laboratory Animal Science : JAALAS.

[39]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy , 2012, Clinical and Translational Allergy.

[40]  H. J. Kueng,et al.  Human TCR Transgenic Bet v 1-Specific Th1 Cells Suppress the Effector Function of Bet v 1-Specific Th2 Cells , 2011, The Journal of Immunology.

[41]  R. Valenta,et al.  Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1 , 2011, The Journal of Immunology.

[42]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[43]  A. Urisu,et al.  A convenient and sensitive allergy test: IgE crosslinking-induced luciferase expression in cultured mast cells , 2010, Allergy.

[44]  H. J. Kueng,et al.  Lipid Rafts, Pseudotyping, and Virus-Like Particles: Relevance of a Novel, Configurable, and Modular Antigen-Presenting Platform , 2010, International Archives of Allergy and Immunology.

[45]  B. Seed,et al.  Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor‐ligand interactions , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  J. Rodriguez-Barbosa,et al.  Development and functional specialization of CD103+ dendritic cells , 2010, Immunological reviews.

[47]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[48]  Daniel M. Altmann,et al.  Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression , 2009, The Journal of experimental medicine.

[49]  S. Scheurer,et al.  Characterization of the allergic T-cell response to Pru p 3, the nonspecific lipid transfer protein in peach. , 2009, The Journal of allergy and clinical immunology.

[50]  S. Wagner,et al.  Role of the polypeptide backbone and post-translational modifications in cross-reactivity of Art v 1, the major mugwort pollen allergen , 2009, Biological chemistry.

[51]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[52]  R. Valenta,et al.  Heterogeneity of commercial timothy grass pollen extracts , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[53]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[54]  Y. Ohya,et al.  Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects. , 2007, The Journal of allergy and clinical immunology.

[55]  Y. Belkaid,et al.  A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β– and retinoic acid–dependent mechanism , 2007, The Journal of experimental medicine.

[56]  B. Seed,et al.  General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines , 2007, Journal of Virology.

[57]  R. Walker,et al.  Live attenuated versus inactivated influenza vaccine in infants and young children. , 2007, The New England journal of medicine.

[58]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[59]  B. Seed,et al.  Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules , 2006, Proceedings of the National Academy of Sciences.

[60]  T. Kündig,et al.  Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. , 2006, The Journal of allergy and clinical immunology.

[61]  H. Malling,et al.  Side‐effects of allergen‐specific immunotherapy. A prospective multi‐centre study , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[62]  H. Blau,et al.  Optimizing Techniques for Tracking Transplanted Stem Cells In Vivo , 2005, Stem cells.

[63]  H. Grönlund,et al.  Rational design of hypoallergens applied to the major cat allergen Fel d 1 , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[64]  C. Akdis,et al.  Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells , 2004, The Journal of experimental medicine.

[65]  R. Valenta.  The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.

[66]  H. Groux,et al.  Differentiation of Regulatory T Cells 1 Is Induced by CD2 Costimulation1 , 2001, The Journal of Immunology.

[67]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[68]  C. Akdis,et al.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. , 1996, The Journal of clinical investigation.

[69]  C. Akdis,et al.  Food allergy: Update on prevention and tolerance. , 2018, The Journal of allergy and clinical immunology.

[70]  R. Valenta,et al.  Molecular Aspects of Allergens and Allergy. , 2018, Advances in immunology.

[71]  P. Valent,et al.  Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. , 2011, Molecular immunology.

[72]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[73]  B. Seed,et al.  Immune deficiencies , infection , and systemic immune disorders Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules , 2009 .